PR Newswire Clinical TrialsOriginal article
Ribo presenta la solicitud para un ensayo clínico en Europa del estudio de fase I con el siRNA RBD3133
Phase 1RBD3133Positive
AI Analysis
Summary
Suzhou Ribo Life Science and subsidiary Ribocure Pharmaceuticals AB submitted a clinical trial application in Europe for Phase 1 study of siRNA candidate RBD3133 targeting INHBE.
Clinical Trial Data
Phase
1
Outcome Details
Clinical trial application submitted in Europe
Importance:5/10
Sentiment:
0.30
siRNAPhase 1EuropeClinical trialINHBE target
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 8, 2026 10:44 AM